EUVIMEDEUVIMED entdecken
Crossref

Controlling the Size and Shape of Monoclonal Antibody Particles through Crystallization Process Design

L Codan iD, P Larpent iD, R Kalapos-Dobszay iD, B Medrán, P Reichert, E Sirota iD, A Cote

Molecular Pharmaceutics · 01.06.2026 · 23 (6) · 3383-3396

DOI: 10.1021/acs.molpharmaceut.6c00046 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 12.05.2026. Verfasst von L Codan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Process Research and Development, MSD Werthenstein BioPharma, Industrie Nord 1, CH-6105 Schachen LU, Switzerland. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 17 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedCrystallizationPolyethylene GlycolsParticle SizeCaffeineDextran SulfateFiltration

Stichwörter der Autor:innen

additivescrystallizationcrystallization agentsfiltrationisothermal batch crystallizationmonoclonal antibodiesprocess optimizationseeded processessemicontinuous crystallizations

Substanzen

Antibodies, MonoclonalPolyethylene GlycolsCaffeineDextran SulfateAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Process Research and Development, MSD Werthenstein BioPharma, Industrie Nord 1, CH-6105 Schachen LU, Switzerland.
  • Analytical Research and Development, MSD Werthenstein BioPharma, Industrie Nord 1, CH-6105 Schachen LU, Switzerland.
  • Protein and Structural Chemistry, Merck & Co., Inc., Rahway, New Jersey 07065, United States.
  • Analytical Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States.
  • Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States.

ORCID-Profile: L Codan, P Larpent, R Kalapos-Dobszay, E Sirota

Zitieren

APA

Codan, L., Larpent, P., Kalapos-Dobszay, R., Medrán, B., Reichert, P., Sirota, E., & Cote, A. (2026). Controlling the Size and Shape of Monoclonal Antibody Particles through Crystallization Process Design. Molecular Pharmaceutics, 23(6), 3383-3396. https://doi.org/10.1021/acs.molpharmaceut.6c00046

Vancouver

Codan L, Larpent P, Kalapos-Dobszay R, Medrán B, Reichert P, Sirota E, et al. Controlling the Size and Shape of Monoclonal Antibody Particles through Crystallization Process Design. Molecular Pharmaceutics. 2026;23(6):3383-3396. doi:10.1021/acs.molpharmaceut.6c00046

BibTeX
@article{Codan2026,
  author = {Codan, L and Larpent, P and Kalapos-Dobszay, R and Medrán, B and Reichert, P and Sirota, E and Cote, A},
  title = {Controlling the Size and Shape of Monoclonal Antibody Particles through Crystallization Process Design},
  journal = {Molecular Pharmaceutics},
  year = {2026},
  volume = {23},
  number = {6},
  pages = {3383--3396},
  doi = {10.1021/acs.molpharmaceut.6c00046}
}
Kostenlos starten →